Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor
- PMID: 16622124
- DOI: 10.1093/jnci/djj133
Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor
Abstract
Background: We previously synthesized a novel s-triazine derivative, ZSTK474 [2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine], that strongly inhibited the growth of tumor cells. We identified its molecular target, investigated its effects on cellular signaling pathways, and examined its antitumor efficacy and toxicity in vivo.
Methods: We used COMPARE analysis of chemosensitivity measurements from 39 human cancer cell lines and identified phosphatidylinositol 3-kinase (PI3K) as a molecular target for ZSTK474. PI3K was immunoprecipitated from A549 cell lysates, and its activity was measured by assessing the incorporation of 32P into phosphatidylinositol. We used the crystal structure of the PI3K-LY294002 complex to model the binding of ZSTK474 to PI3K (where LY294002 is a known PI3K inhibitor). PI3K downstream activity was analyzed by immunoblotting. Antitumor activity of ZSTK474 was examined against A549, PC-3, and WiDr xenografts in nude mice. Phosphorylation of Akt, a serine/threonine protein kinase and a major signaling component downstream of PI3K, was assessed in vivo by immunohistochemistry.
Results: PI3K was identified as a molecular target for ZSTK474 by COMPARE analysis. We confirmed that ZSTK474 directly inhibited PI3K activity more efficiently than the PI3K inhibitor LY294002. At concentrations of 1 microM, ZSTK474 and LY2194002 reduced PI3K activity to 4.7% (95% confidence interval [CI] = 3.2% to 6.1%) and 44.6% (95% CI = 38.9% to 50.3%), respectively, of the untreated control level. Molecular modeling of the PI3K-ZSTK474 complex indicated that ZSTK474 could bind to the ATP-binding pocket of PI3K. ZSTK474 inhibited phosphorylation of signaling components downstream from PI3K, such as Akt and glycogen synthase kinase 3beta, and mediated a decrease in cyclin D1 levels. ZSTK474 administered orally to mice had strong antitumor activity against human cancer xenografts without toxic effects in critical organs. Akt phosphorylation was reduced in xenograft tumors after oral administration of ZSTK474.
Conclusion: ZSTK474 is a new PI3K inhibitor with strong antitumor activity against human cancer xenografts without toxic effects in critical organs. ZSTK474 merits further investigation as an anticancer drug.
Similar articles
-
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms.Cancer Sci. 2007 Oct;98(10):1638-42. doi: 10.1111/j.1349-7006.2007.00580.x. Epub 2007 Aug 16. Cancer Sci. 2007. PMID: 17711503 Free PMC article.
-
Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest.Biochem Biophys Res Commun. 2009 Jan 30;379(1):104-9. doi: 10.1016/j.bbrc.2008.12.015. Epub 2008 Dec 16. Biochem Biophys Res Commun. 2009. PMID: 19094964
-
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.Eur J Cancer. 2010 Apr;46(6):1111-21. doi: 10.1016/j.ejca.2010.01.005. Epub 2010 Feb 1. Eur J Cancer. 2010. PMID: 20129775
-
ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.Acta Pharmacol Sin. 2010 Sep;31(9):1189-97. doi: 10.1038/aps.2010.150. Epub 2010 Aug 23. Acta Pharmacol Sin. 2010. PMID: 20729870 Free PMC article. Review.
-
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.Cancer Sci. 2008 Sep;99(9):1734-40. doi: 10.1111/j.1349-7006.2008.00891.x. Epub 2008 Jul 4. Cancer Sci. 2008. PMID: 18616528 Free PMC article. Review.
Cited by
-
β-carboline derivative Z86 attenuates colorectal cancer cell proliferation and migration by directly targeting PI3K.Nat Prod Bioprospect. 2024 Jan 3;14(1):3. doi: 10.1007/s13659-023-00422-y. Nat Prod Bioprospect. 2024. PMID: 38169019 Free PMC article.
-
Design and Synthesis of 1,3,5-Triazines or Pyrimidines Containing Dithiocarbamate Moiety as PI3Kα Selective Inhibitors.ACS Med Chem Lett. 2023 Aug 9;14(9):1266-1274. doi: 10.1021/acsmedchemlett.3c00287. eCollection 2023 Sep 14. ACS Med Chem Lett. 2023. PMID: 37736169
-
Deciphering the Biology of Circulating Tumor Cells through Single-Cell RNA Sequencing: Implications for Precision Medicine in Cancer.Int J Mol Sci. 2023 Aug 2;24(15):12337. doi: 10.3390/ijms241512337. Int J Mol Sci. 2023. PMID: 37569711 Free PMC article. Review.
-
The lysosomal LAMTOR / Ragulator complex is essential for nutrient homeostasis in brown adipose tissue.Mol Metab. 2023 May;71:101705. doi: 10.1016/j.molmet.2023.101705. Epub 2023 Mar 11. Mol Metab. 2023. PMID: 36907508 Free PMC article.
-
Subtype-selective induction of apoptosis in translocation-related sarcoma cells induced by PUMA and BIM upon treatment with pan-PI3K inhibitors.Cell Death Dis. 2023 Feb 27;14(2):169. doi: 10.1038/s41419-023-05690-7. Cell Death Dis. 2023. PMID: 36849535 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials